

Japan's Eisai helps Alzheimer's patients access ADUHELM post-FDA approval

08 June 2021 | News

ADUHELM (aducanumab-avwa), a human monoclonal antibody, is the first and only Alzheimer's disease treatment



Following U.S. Food and Drug Administration's (FDA) accelerated approval of ADUHELM™ (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain, Biogen and Eisai Inc., U.S. subsidiary of Japanese firm Eisai Co., Ltd., have announced a range of programs intended to support access for all qualified patients, including traditionally underserved populations.

These initiatives aim to help patients and their families understand the disease, navigate the diagnostic journey, secure culturally competent care and afford treatment.

ADUHELM (aducanumab-avwa), a human monoclonal antibody, is the first and only Alzheimer's disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. ADUHELM is indicated for the treatment of Alzheimer's disease.

"ADUHELM is the first new treatment for Alzheimer's disease to be approved in the U.S. in nearly 20 years, bringing long-awaited hope for patients and families living with this neurodegenerative disease," said Ivan Cheung, Chairman of Eisai Inc. and President, Neurology Business Group, Eisai Co., Ltd. "It is critically important for Eisai and Biogen to not only establish these access programs but to champion their reach, especially in underserved patient communities."